Russell Investments Group Ltd. Boosts Stake in Illumina, Inc. $ILMN

Key Points

• Russell Investments raised its stake in Illumina by 22.3%, adding 46,361 shares to hold 253,810 shares worth about $24.07 million (roughly 0.17% of the company).
• Illumina topped quarterly expectations with $1.35 EPS and $1.16 billion in revenue, and set FY2026 guidance of 5.050–5.200 EPS.
• Wall Street is mixed: the consensus rating is "Hold" with a $129.69 price target, while individual analyst ratings range from sell to strong-buy.

Russell Investments Group Ltd. lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 22.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 253,810 shares of the life sciences company's stock after purchasing an additional 46,361 shares during the quarter. Russell Investments Group Ltd. owned 0.17% of Illumina worth $24,070,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ILMN. Inceptionr LLC bought a new position in Illumina in the third quarter valued at $1,037,000. Dynamic Technology Lab Private Ltd bought a new stake in Illumina during the third quarter worth about $511,000. Vinva Investment Management Ltd purchased a new position in shares of Illumina in the 3rd quarter worth about $323,000. Parallel Advisors LLC boosted its holdings in shares of Illumina by 4.7% in the 3rd quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company's stock worth $269,000 after purchasing an additional 128 shares in the last quarter. Finally, Guardian Partners Inc. increased its position in shares of Illumina by 20.2% during the 3rd quarter. Guardian Partners Inc. now owns 18,121 shares of the life sciences company's stock valued at $1,853,000 after purchasing an additional 3,050 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research reports. Piper Sandler decreased their price objective on Illumina from $195.00 to $170.00 and set an "overweight" rating on the stock in a report on Monday, February 9th. JPMorgan Chase & Co. cut their target price on Illumina from $130.00 to $120.00 and set a "neutral" rating for the company in a research note on Friday, February 6th. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $150.00 and gave the company a "hold" rating in a research report on Monday, January 26th. Wall Street Zen raised shares of Illumina from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 14th. Finally, TD Cowen restated a "hold" rating on shares of Illumina in a report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $129.69.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company's stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.60% of the company's stock.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $115.56 on Friday. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $133.45 and a 200-day moving average price of $119.68. The company has a market cap of $17.67 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 2.32 and a beta of 1.45. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.10 billion. During the same period last year, the firm earned $0.95 earnings per share. Illumina's quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.